An investigational device exemption (IDE) is an FDA authorization that allows a medical device that hasn’t yet been approved for sale to be used in a clinical study on human subjects. It essentially creates a legal pathway to ship and test an experimental device so researchers can collect the safety and effectiveness data needed for eventual market approval. Without an IDE, using an unapproved device on people would violate federal law.
The exemption lifts several regulatory requirements that normally apply to commercially distributed devices. While a study is underway, sponsors don’t need to submit a premarket approval application or a 510(k) notification, register their manufacturing establishment, or list the device with the FDA. They are still required to follow design control standards, but other parts of the quality system regulation are waived during the investigation period.
How Risk Classification Shapes the Process
Not every investigational device study requires a full IDE application submitted to the FDA. The determining factor is risk. Devices fall into one of two categories: significant risk (SR) or nonsignificant risk (NSR), and the classification changes how much regulatory oversight the study receives.
A device is considered significant risk if it meets any of these criteria:
- Implants: The device is intended to be implanted in the body and poses a potential for serious harm.
- Life-sustaining or life-supporting: The device is meant to support or sustain human life and poses a potential for serious harm.
- Substantially important for diagnosis or treatment: The device plays a major role in diagnosing, curing, or treating disease and poses a potential for serious harm.
- General serious risk: The device otherwise presents a potential for serious risk to participants’ health, safety, or welfare.
The risk determination is based on the proposed use of the device in that specific investigation, not just the device itself. An institutional review board (IRB) should also consider whether participants will need additional procedures, like surgery, as part of the study, since the procedure itself adds risk. The sponsor makes the initial risk call and presents it to the IRB, which can agree or disagree. If a dispute arises, the FDA is the final arbiter.
Significant risk device studies require a full IDE application submitted to the FDA, plus IRB approval at every study site. Nonsignificant risk studies follow an abbreviated process: they need IRB approval and must comply with a shortened list of IDE regulations, but they do not require a separate FDA submission. This distinction saves considerable time and cost for lower-risk investigations.
What an IDE Application Includes
For significant risk studies, the sponsor submits a formal IDE application to the FDA. The application must contain a complete report of all prior investigations of the device, covering bench testing, animal studies, and any earlier human use. It also requires an investigational plan that details the study’s purpose, the protocol, the risk analysis, a description of the device, monitoring procedures, and how the study will protect participants.
Every investigational device, or its immediate packaging, must carry a specific label statement: “CAUTION — Investigational device. Limited by Federal (or United States) law to investigational use.” The label also has to list all relevant contraindications, hazards, adverse effects, warnings, and precautions. Devices shipped only for animal research carry a different label noting they are restricted to laboratory animal use.
The 30-Day FDA Review Window
Once the FDA receives an IDE application, a 30-day clock starts. If the agency doesn’t respond within that window, the IDE is considered approved by default, and the study can begin (assuming IRB approval is already in place). In practice, the FDA often responds before the 30 days are up, either approving the application outright, approving it with conditions, or disapproving it. Sponsors receive notification by email.
This 30-day timeline is notably faster than the review periods for premarket approval applications, which can take months or longer. The relatively quick turnaround reflects the FDA’s interest in facilitating clinical research while still maintaining oversight of studies that could put participants at risk.
The Role of the IRB
An institutional review board is an independent committee formally designated to review and monitor biomedical research involving human subjects. For IDE studies, the IRB serves as a critical safety layer between the sponsor and the study participants.
The IRB reviews the research protocol, informed consent documents, and the sponsor’s risk determination before any participants are enrolled. It has the authority to approve the study, require modifications before granting approval, or disapprove it entirely. Approval isn’t a one-time event. The IRB must continue monitoring the investigation throughout its duration, reviewing progress reports, adverse events, and any protocol changes. If an IRB determines that a study involves a significant risk device (overriding the sponsor’s initial assessment), it must notify the investigator and, when appropriate, the sponsor, which then triggers the need for a full IDE submission to the FDA.
Adverse Event Reporting Requirements
When something unexpected goes wrong during an IDE study, both investigators and sponsors have mandatory reporting obligations with tight deadlines. If an investigator encounters an unanticipated adverse device effect, they must report it to the sponsor and their reviewing IRB within 10 working days of first learning about it.
The sponsor then has a separate but parallel obligation. After receiving that report and evaluating it, the sponsor must notify the FDA, all reviewing IRBs across every study site, and all investigators within 10 working days of first receiving notice. These dual timelines ensure that safety signals reach every party involved quickly enough to protect participants still enrolled in the study.
How IDEs Fit Into the Bigger Regulatory Picture
An IDE is not an approval to sell a device. It’s a temporary permission slip that allows research to happen. The data collected under an IDE typically feeds into a premarket approval (PMA) application or, in some cases, a 510(k) submission, which is the actual pathway to commercial distribution. PMA applications carry substantial user fees: for fiscal year 2025, the base fee for a standard premarket application is $540,783 (with a reduced rate of $135,196 for small businesses).
The IDE itself does not carry those same fees. Its value is in clearing the legal and regulatory path so that a sponsor can generate the clinical evidence the FDA will eventually require. For companies developing novel, high-risk devices like new cardiac implants, surgical robots, or diagnostic technologies, the IDE is often the most consequential regulatory milestone before market approval. It determines whether the clinical trial can proceed, how many sites can participate, and under what conditions the device can be tested in humans.
Some investigations are exempt from IDE requirements altogether. Devices that are already legally marketed, when used in accordance with their approved labeling, generally do not need an IDE for studies. Diagnostic devices used in certain ways may also qualify for exemptions, as can consumer preference testing and studies that don’t involve clinical use of the device on human subjects.